Lindsay Rosenwald

Lindsay Rosenwald, M.D. is a New York-based venture capitalist and hedge fund manager with 10 year track record as pharmaceutical and biotechnology financier. He is the president of the Rosenwald Foundation, a charitable foundation based in New York which helps further the advancement of biotechnology by continuing research and development. He is also founder and chairman of Paramount Capital Asset Management, Paramount Capital, Inc., and Paramount Capital Investment, LLC. Dr. Rosenwald is also director of Neose Technologies, Inc., Interneuron Pharmaceuticals, Inc., and Keyx, Inc.
In addition, he serves as director of several pubic and private biotechnology companies and is a member of the Columbia-Presbyterian Health Sciences Advisory Counsel.

Dr. Rosenwald’s contributions to the biotechnology industry are numerous and significant. As one of the world’s most creative entrepreneurs in the history of the industry, he holds the record for the quickest drug development FDA approval time, developed a treatment for leukemia in under 30 months, and holds the record for the highest price ever paid for a drug that had not yet completed clinical development. Dr. Rosenwald successfully launched Cougar Biotechnology, which sold to Johnson and Johnson for one billion dollars in 2009.

Dr. Lindsay Rosenwald received his Bachelor of Science from Pennsylvania State University in 1977 and earned his degree in Finance. After receiving his Doctor of Medicine from Temple University School of Medicine in 1983, he completed a medical internship at Abington Hospital in 1984. For two years he maintained a private practice, and in 1986 he moved to Wall Street to develop his career as a physician/analyst, a rare position in his field at the time. Dr. Lindsay Rosenwald started Paramount Biocapital in 1991, a NASD-affiliated organization that focuses on the development of promising in licensed drug candidates, which has since raised nearly $950 millions dollars for its portfolio companies.

With over 20 years’ experience in biotechnology, biomedicine, and finance, Dr. Rosenwald continues to stand recognized as a leader in research and development. His rich background in both finance and medicine give him the distinctive ability to create and develop cutting-edge opportunities of expansion in both fields.

As a proud Board of Directors member of the Republican Jewish Coalition, Dr. Lindsay Rosenwald’s professional biography is displayed on their Web site, www.rjchq.org. It gives a little information about the company he co-founded, Paramount Capital Assets inc., which is a prominent financing company in the biotechnology field. The company focuses on venture capital, hedge funds, and private equity.

Dr. Lindsay Rosenwald appears on the Muckety Maps Web site, which illustrates his connection to Paramount Capital Assets Management Inc. and the Republican Jewish Coalition as a (spiderweb) diagram.

Dr. Lindsay Rosenwald is a member of the Wellness.com community. He graduated from TempleUniversityMedicalSchool and is currently working at a general practitioner in New York City. Dr. Lindsay Rosenwald provides a variety of services that range from standard immunizations to skin biopsies and menopause treatments.

As a member of the NYICECATS, which is a Jewish Orthodox Youth Hockey Organization, Dr. Lindsay Rosenwald has been honored by his fellow members. During the third and fourth annual Captain’s Dinner, he was presented with gifts, including a Bauers 190, by Neil Herskowitz who is the Director of Manhattan Pharmaceuticals Inc. As the dinner went on, Dr. Lindsay Rosenwald announced his commitment to 25 more years of playing hockey at the Piers. When the dinner ended the celebration closed with the “Golden Balls” award ceremony.

Dr. Lindsay Rosenwald’s contribution of $61, 800 to the McCain Victory Committee appears in the Huffington Post’s FundRace of 2008.

More About Lindsay Rosenwald

One more extremely important profile firm, founded and managed by Lindsay
Rosenwald M.D. is Keryx Bio pharmaceuticals. It is developing a compound referred
to as Sulonex, which is an oral treatment for diabetic nephropathy. It was licensed in
the Alfa Wassermann Group, a privately held pharmaceutical firm in Bologna, Italy. If
approved, Sulonex will probably be marketed to 15 million folks diagnosed with Sort
2 diabetes as well since the one to a couple of million patients with Form 1 diabetes.
Vital Bio Sciences, LLC, a global pharmaceutical progress and wellness care
investment firm, was founded and managed by Dr. Lindsay A. Rosenwald in 1991.
The organization facilitates drug advancement, scientific service and dedicates itself
to discovering and building novel therapeutic medicines with big likely. By assessing
promising drug candidates worldwide, Important may be able to create, nurture, and
assistance much more than 40 lifestyle sciences corporations, academic centers,
biotechnology and pharmaceutical firms in excess of the past 19 years, which
includes 20 within the last 48 months. Latest Profile Corporations have around 40
solution candidates advancing by means of clinical trials.

Exclusive tactic to bio tech purchase: Organization and product or service
advancement are just two pieces inside the Very important puzzle. An affiliate
of Very important Bio Sciences - Important Bio Budget, Inc., is often a FINRA
registered broker-dealer that, among other activities, raises capital for the Vital
Portfolio Organizations. It rose in excess of some billion with the Portfolio Firms;
several instances that quantity has become raised for Paramount Organizations
by other entities. Though venture money and private equity firms tend to become
investment-oriented, Paramount's bias is about the operational side. It establishes
firms on the ground up, employing its very own budget and eventually funds raised
from diverse exclusive and institutional investors through Important Bio Sciences
and other banks and broker-dealers on Wall Street. Absolutely, Lindsay Rosenwald
Paramount's practical knowledge in finance and company places aids make the
design appealing to potential licensors and chief executive officers.
With Very important Funds generally handling accounting, financial, current market
analytical and legal functions, managers of its Portfolio Companies can focus
generally on driving drug candidates by means of the clinic and producing worth for
shareholders, licensors and also the patient community.

Infrastructure and Corporation Building at Vital: Important involves an extensive
support infrastructure with encounter in licensing, clinical advancement, corporate
operations, and navigating regulatory pathways. Every new profile organization
at Very important Bio Sciences is constructed all-around intriguing science and
commercial prospective. The Portfolio Corporations are operated by Paramount
Money through a dedicated first-class management in the company level, as
properly as a result of small business and clinical progress and operations
specialists operating for extremely important in New York. Chelsea Therapeutics, for
example, at first was made or founded by Dr. Lindsay Rosenwald all-around a novel
anti-folate being produced to the cure of inflammatory ailments that incorporated
rheumatoid arthritis (RA) and psoriasis.

When we discuss about science and medicine, we might be talking about biotechnology. It is the use of microbiological substance and bacteria like enzymes to perform manufacturing and industrial process. And when we talk about biotechnology, we might end up talking about a person who succeeded in this field for his brilliant mind and hard work. The person is none other than Dr. Lindsay Rosenwald, who has received tons of awards, certifications, and honours. He has gained people’s respect, especially to those professionals of his kind. Due to his achievements and accomplishment, most people believed that his works are magnificent and outstanding.

He had his first company Paramount was established in the year 1991. It provided funds to smaller and starting biotechnology companies which had plans to develop new drugs and treatments. Although he chose which companies had the greater possibility to succeed, he was able to help them improve until they can stand on their own. He had been great to people who has passion to succeed in the field of life science.

One of the companies that he had established was Polarx, developed an arsenic trioxide injection which is commonly known as Trisenox, a treatment for acute promyelocytic leukemina or the LPA; Another one is the Peramivir, which was developed by Biocryst pharmaceuticals, is an antiviral drug to treat patients suffering from influenza, which are suspected to have a disease called H1N1; Sypress Biosciences who created and developed Savella and Prosorba Column, the first mentioned which is now known as Milnacipran, is a SNRI used to treat disorders like major depression and fibromyalgia. On the other hand, Prosorba Column is a device to filter plasma and used to treat for severe psoriatic arthritis or rheumatoid arthritis; another great pharmaceutical that contributed great help to mankind and made him more famous and honourable is the Titan Pharmaceuticals, who introduced Fanapt which is now previously known as Zomaril but we now call it Iloperidone. It is an antipsychotic drug which is a treatment for schizophrenia. All the above mentioned drugs were approved by the American Food and Drug Administration of the FDA to be used in the United States. These are just some of the made him gain honors. It was made possible with his help and guidance. That is why, each time that these pharmaceuticals developed another treatment aside from the I have mentioned above are, most likely, dedicated under his name.

Dr. Lindsay Rosenwald stayed humble even while on the peak of his career. He is an honorary individual who tried to help a lot of people with his generosity and kind heart and still trying to help even more. In fact, he also has established non-profit institutions and foundations. He also has a strong belief that since he has made biotechnology better compare to the last 2 decades, it will improve more in the next decade or two.